Development of first-in-class ST2 inhibitors for treating graft-versus-host diseasePACZESNY, SOPHIE and YANG, CHAO-YIENational Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 1R01HL141432-01A1), $703,200USD, 02/01/2019 -- 01/31/2023